Cross-resistance to clinically used tyrosine kinase inhibitors sunitinib, sorafenib and pazopanib
与临床使用的酪氨酸激酶抑制剂舒尼替尼、索拉非尼和帕唑帕尼存在交叉耐药性
期刊:Cellular Oncology
影响因子:
doi:10.1007/s13402-015-0218-8
Kristy J Gotink, Maria Rovithi, Richard R de Haas, Richard J Honeywell, Henk Dekker, Dennis Poel, Kaamar Azijli, Godefridus J Peters, Henk J Broxterman, Henk M W Verheul
